In The News: Henry Ford Health System and G3 Pharmaceuticals to Develop and Commercialize Treatment for Diastolic Heart Failure

November 1, 2018

G3 Pharmaceuticals, a development-stage biopharmaceutical company located in Burlington, MA, and Henry Ford Health System, have announced the signing of an exclusive license and option agreement for the development and commercialization of galectin-3 inhibitors for treatment of diastolic heart failure, also known as heart failure with preserved ejection fraction or HFpEF.

Read the full article here:

https://www.prnewswire.com/news-releases/g3-pharmaceuticals-signs-exclusive-license-and-option-agreement-for-treating-diastolic-heart-failure-hfpef-by-inhibiting-galectin-3-300739964.html

X

Cookie Consent

We use cookies to improve your web experience. By using this site, you agree to our Terms of Use. Read our Internet Privacy Statement to learn what information we collect and how we use it.

Accept All Cookies